AGP Executive Report
Last update: 11 hours agoResearch: Texas A&M scientists found polyethylene microplastics worsened signs of fatty liver disease in mice, especially alongside an unhealthy diet; effects in people remain unknown. Drug Safety: FDA inspectors cited 14 production concerns at Houston RX, which recalled 64 compounded tirzepatide vials over sterility concerns—an alert for Texans using injectable weight-loss drugs. Community Care: Longview’s GLOW program has reduced emergency calls and ER visits among high-need residents, cutting about $1.5 million in charges, but key grants expire within a year and leaders are seeking new funding. Water Safety: Ventana residents were told to boil water after a pressure drop raised concerns about bacterial contamination. Surgical Care: A UTHealth Houston-led analysis of 2 million patients found GLP-1 users had slightly lower rates of post-surgery heart complications and infections; it doesn’t show the drugs caused the difference or settle whether patients should pause treatment. Rural Hospitals: Texas providers are sharing $78 million in federal grants for workforce development, chronic-disease prevention and facility upgrades. Medical Bills: A new report says Texas hospitals could do more to connect patients with financial assistance before sending large bills.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pharmacists Step Up on Test-To-Treat This American Pharmacist Month]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29570567-950808016-f64292d89a3e9deb400987e3914b7e1dbaef5f2f-5120x2880-200x113.jpeg)
